Date: 2016-04-01
Type of information: Nomination
Compound:
Company: Keryx Biopharmaceuticals (USA - NY)
Therapeutic area: Renal diseases - Kidney diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 1, 2016, Keryx Biopharmaceuticals announced appointment of two industry leaders to Keryx's board of directors, which increases the size of the company's board to 10 members. These appointments are expected to bring deep, relevant industry experience to Keryx at an important time in the company's growth.
On March 31, 2016 , Steven C. Gilman , Ph.D., and Michael Rogers were elected as independent directors to Keryx's board of directors, effective immediately. Dr. Gilman brings broad scientific and development expertise to Keryx's board having led or built several successful R&D organizations; he served most recently, for seven years, as chief scientific officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Mr. Rogers has been the chief financial officer of Acorda Therapeutics since October 2013 and brings to Keryx valuable experience from his two decades of financial leadership in the biotech industry.
Four current board members, Michael Tarnok , Jack Kaye , Senator Wyche Fowler, Jr. and Joseph Feczko , M.D. will not seek re-election to the company's Board when their terms expire at Keryx's 2016 Annual Meeting in May. Following conclusion of the annual meeting, Keryx will reduce the size of the company's board to six members. Additionally, John P. Butler , an independent director, was elected by the Board to serve as chairman, a role he will assume beginning at Keryx's 2016 Annual Meeting.
Financial terms:
Latest news:
